• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Cuba encouraged by early trials of homegrown COVID-19 vaccine

firstwordpharmaJune 21, 2021

Tag: Cuba , COVID-19 , Vaccine

Cuba's state-run biopharmaceutical corporation BioCubaFarma said preliminary data from late phase trials showed that the Soberana 2 vaccine candidate for COVID-19 had 62% efficacy with just two of its three doses, as reported Fidelity.

Cuba encouraged by early trials of homegrown COVID-19 vaccine

"In a few weeks we should have the results for the efficacy with three doses which we expect will be superior," said Vicente Vérez, director of the Finlay Vaccine Institute, which developed Soberana 2.

Several countries from have expressed an interest in buying Cuba's vaccines, and Iran started producing Soberana 2 earlier this year as part of late-phase trials.

Previous:Israeli scientists find promising target for breast cancer and other cancer therapeutics

Next:China's Sinopharm COVID-19 vaccines arrive in Thailand

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Cuba encouraged by early trials of homegrown COVID-19 vaccine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Basic dry bath incubator SDBI300

Basic dry bath incubator SDBI300
Hualan BIO Influenza Vaccine (Split virion)

Hualan BIO Influenza Vaccine (Split virion)
Inactivated Influenza Vaccine (Split virion)with stable quality

Inactivated Influenza Vaccine (Split virion)with stable quality
Desktop Incubator Shaker THZ-82N

Desktop Incubator Shaker THZ-82N
Influenza Vaccine(Split Virion),Inactivated by Hualan Bio

Influenza Vaccine(Split Virion),Inactivated by Hualan Bio
Heating Incubator PYX-DHS-BY

Heating Incubator PYX-DHS-BY
Hualan Biological Influenza Vaccine

Hualan Biological Influenza Vaccine
Hepatitis A (Live) Vaccine, Freeze-Dried

Hepatitis A (Live) Vaccine, Freeze-Dried
High-dose trivalent influenza vaccine

High-dose trivalent influenza vaccine
Sacubatril/Valsartan

Sacubatril/Valsartan

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service